Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Search
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Novartis AG
Clear Filter
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
3
4
5
»
Date / Time
Source
Ticker
Company
Sector
Market Cap
Announcement
22Dec17 21:42
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces Oncology head to retire
15Dec17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces Oncology head to retire
11Dec17 15:50
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38
GNW
0QLR:LON
Novartis AG
Health
208,186m
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10
GNW
0QLR:LON
Novartis AG
Health
208,186m
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00
GNW
0QLR:LON
Novartis AG
Health
208,186m
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
«
1
2
3
4
5
»
Date / Time
Source
Company
% Chg
22Dec17 21:42
GNW
Novartis AG
0.70%
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15
GNW
Novartis AG
0.70%
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00
GNW
Novartis AG
0.70%
Novartis announces Oncology head to retire
15Dec17 06:00
GNW
Novartis AG
0.70%
Novartis announces Oncology head to retire
11Dec17 15:50
GNW
Novartis AG
0.70%
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38
GNW
Novartis AG
0.70%
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15
GNW
Novartis AG
0.70%
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00
GNW
Novartis AG
0.70%
Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15
GNW
Novartis AG
0.70%
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15
GNW
Novartis AG
0.70%
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00
GNW
Novartis AG
0.70%
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15
GNW
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15
GNW
Novartis AG
0.70%
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00
GNW
Novartis AG
0.70%
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15
GNW
Novartis AG
0.70%
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10
GNW
Novartis AG
0.70%
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00
GNW
Novartis AG
0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00
GNW
Novartis AG
0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00
GNW
Novartis AG
0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00
GNW
Novartis AG
0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51
GNW
Novartis AG
0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30
GNW
Novartis AG
0.70%
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00
GNW
Novartis AG
0.70%
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51
GNW
Novartis AG
0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15
GNW
Novartis AG
0.70%
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15
GNW
Novartis AG
0.70%
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15
GNW
Novartis AG
0.70%
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10
GNW
Novartis AG
0.70%
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30
GNW
Novartis AG
0.70%
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05
GNW
Novartis AG
0.70%
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15
GNW
Novartis AG
0.70%
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15
GNW
Novartis AG
0.70%
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00
GNW
Novartis AG
0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00
GNW
Novartis AG
0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55
GNW
Novartis AG
0.70%
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15
GNW
Novartis AG
0.70%
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30
GNW
Novartis AG
0.70%
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00
GNW
Novartis AG
0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00
GNW
Novartis AG
0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15
GNW
Novartis AG
0.70%
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15
GNW
Novartis AG
0.70%
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15
GNW
Novartis AG
0.70%
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15
GNW
Novartis AG
0.70%
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15
GNW
Novartis AG
0.70%
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15
GNW
Novartis AG
0.70%
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15
GNW
Novartis AG
0.70%
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00
GNW
Novartis AG
0.70%
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15
GNW
Novartis AG
0.70%
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15
GNW
Novartis AG
0.70%
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15
GNW
Novartis AG
0.70%
Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05
GNW
Novartis AG
0.70%
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00
GNW
Novartis AG
0.70%
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30
GNW
Novartis AG
0.70%
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15
GNW
Novartis AG
0.70%
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00
GNW
Novartis AG
0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00
GNW
Novartis AG
0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04
GNW
Novartis AG
0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04
GNW
Novartis AG
0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00
GNW
Novartis AG
0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00
GNW
Novartis AG
0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00
GNW
Novartis AG
0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00
GNW
Novartis AG
0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15
GNW
Novartis AG
0.70%
Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10
GNW
Novartis AG
0.70%
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15
GNW
Novartis AG
0.70%
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15
GNW
Novartis AG
0.70%
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20
GNW
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00
GNW
Novartis AG
0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00
GNW
Novartis AG
0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22
GNW
Novartis AG
0.70%
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24
GNW
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20
GNW
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52
GNW
Novartis AG
0.70%
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15
GNW
Novartis AG
0.70%
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00
GNW
Novartis AG
0.70%
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40
GNW
Novartis AG
0.70%
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40
GNW
Novartis AG
0.70%
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35
GNW
Novartis AG
0.70%
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42
GNW
Novartis AG
0.70%
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15
GNW
Novartis AG
0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15
GNW
Novartis AG
0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15
GNW
Novartis AG
0.70%
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15
GNW
Novartis AG
0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15
GNW
Novartis AG
0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10
GNW
Novartis AG
0.70%
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15
GNW
Novartis AG
0.70%
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15
GNW
Novartis AG
0.70%
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00
GNW
Novartis AG
0.70%
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15
GNW
Novartis AG
0.70%
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30
GNW
Novartis AG
0.70%
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30
GNW
Novartis AG
0.70%
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15
GNW
Novartis AG
0.70%
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05
GNW
Novartis AG
0.70%
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15
GNW
Novartis AG
0.70%
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00
GNW
Novartis AG
0.70%
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15
GNW
Novartis AG
0.70%
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10
GNW
Novartis AG
0.70%
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00
GNW
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00
GNW
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00
GNW
Novartis AG
0.70%
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
«
1
2
3
4
5
»
Date / Time
Company
% Chg
22Dec17 21:42
Novartis AG
0.70%
Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22Dec17 06:15
Novartis AG
0.70%
Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
15Dec17 06:00
Novartis AG
0.70%
Novartis announces Oncology head to retire
15Dec17 06:00
Novartis AG
0.70%
Novartis announces Oncology head to retire
11Dec17 15:50
Novartis AG
0.70%
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
10Dec17 15:38
Novartis AG
0.70%
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
08Dec17 06:15
Novartis AG
0.70%
Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine
07Dec17 06:00
Novartis AG
0.70%
Novartis tender offer for Advanced Accelerator Applications commences
06Dec17 18:15
Novartis AG
0.70%
Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to...
30Nov17 06:15
Novartis AG
0.70%
Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
29Nov17 22:00
Novartis AG
0.70%
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
27Nov17 06:15
Novartis AG
0.70%
Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
20Nov17 06:15
Novartis AG
0.70%
Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children
15Nov17 14:00
Novartis AG
0.70%
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
14Nov17 06:15
Novartis AG
0.70%
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
14Nov17 06:10
Novartis AG
0.70%
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
13Nov17 17:00
Novartis AG
0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 17:00
Novartis AG
0.70%
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
13Nov17 06:00
Novartis AG
0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 06:00
Novartis AG
0.70%
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
13Nov17 02:51
Novartis AG
0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
12Nov17 18:30
Novartis AG
0.70%
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure
11Nov17 13:00
Novartis AG
0.70%
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
10Nov17 22:51
Novartis AG
0.70%
Novartis brolucizumab (RTH258) demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity in nAMD, a leading cause of blindness
08Nov17 06:15
Novartis AG
0.70%
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic breast cancer
07Nov17 06:15
Novartis AG
0.70%
Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage
06Nov17 06:15
Novartis AG
0.70%
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06Nov17 06:10
Novartis AG
0.70%
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
02Nov17 20:30
Novartis AG
0.70%
Novartis and Amgen announce expanded collaboration with Banner Alzheimer's Institute in pioneering prevention program
01Nov17 13:05
Novartis AG
0.70%
Novartis presents data at ASH for patients with serious blood disorders like lymphoma, leukemia and sickle cell disease
31Oct17 06:15
Novartis AG
0.70%
Novartis submits application to FDA for KymriahTM (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy
30Oct17 06:15
Novartis AG
0.70%
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30Oct17 06:00
Novartis AG
0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
30Oct17 06:00
Novartis AG
0.70%
Novartis announces the planned acquisition of Advanced Accelerator Applications to strengthen oncology portfolio
28Oct17 07:55
Novartis AG
0.70%
Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a
27Oct17 06:15
Novartis AG
0.70%
Sandoz proposed biosimilar pegfilgrastim accepted by EMA for regulatory review
25Oct17 16:30
Novartis AG
0.70%
Novartis confirms leadership in multiple sclerosis (MS) with scientific advancements and new data presented at ECTRIMS
24Oct17 06:00
Novartis AG
0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
24Oct17 06:00
Novartis AG
0.70%
Novartis delivered growth on top and bottom line in all divisions in Q3
23Oct17 06:15
Novartis AG
0.70%
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
18Oct17 06:15
Novartis AG
0.70%
Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
06Oct17 06:15
Novartis AG
0.70%
Alcon receives CE Mark for first-of-its-kind AutonoMe(TM) preloaded intraocular lens (IOL) delivery system with Clareon® IOL
02Oct17 06:15
Novartis AG
0.70%
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
28Sep17 06:15
Novartis AG
0.70%
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
22Sep17 06:15
Novartis AG
0.70%
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
20Sep17 06:15
Novartis AG
0.70%
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
16Sep17 15:00
Novartis AG
0.70%
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
14Sep17 06:15
Novartis AG
0.70%
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
13Sep17 06:15
Novartis AG
0.70%
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
12Sep17 06:15
Novartis AG
0.70%
Sandoz proposed biosimilar rituximab accepted for review by the FDA
10Sep17 23:05
Novartis AG
0.70%
Novartis Phase III study demonstrates adjuvant Tafinlar® + Mekinist® reduced the risk of disease recurrence by 53% in patients with resected BRAF V600 mutation-positive melanoma
09Sep17 10:00
Novartis AG
0.70%
Novartis presents new data at EURETINA 2017 confirming Lucentis® efficacy and durability vs aflibercept
07Sep17 21:30
Novartis AG
0.70%
Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced monthly migraine days in patients who failed previous preventive therapies
05Sep17 06:15
Novartis AG
0.70%
Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
04Sep17 06:00
Novartis AG
0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
04Sep17 06:00
Novartis AG
0.70%
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
30Aug17 16:04
Novartis AG
0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
30Aug17 16:04
Novartis AG
0.70%
Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
28Aug17 08:00
Novartis AG
0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
28Aug17 08:00
Novartis AG
0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
27Aug17 10:00
Novartis AG
0.70%
Novartis announces analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned
27Aug17 10:00
Novartis AG
0.70%
Novartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
24Aug17 06:15
Novartis AG
0.70%
Novartis appoints Bertrand Bodson as Chief Digital Officer
24Aug17 06:10
Novartis AG
0.70%
Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
21Aug17 06:15
Novartis AG
0.70%
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
25Jul17 06:15
Novartis AG
0.70%
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
21Jul17 12:20
Novartis AG
0.70%
Novartis receives positive CHMP opinion for Rydapt® (midostaurin) for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
18Jul17 06:00
Novartis AG
0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
18Jul17 06:00
Novartis AG
0.70%
Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products
14Jul17 18:22
Novartis AG
0.70%
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
12Jul17 22:24
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
12Jul17 22:20
Novartis AG
0.70%
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
06Jul17 07:52
Novartis AG
0.70%
Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis
29Jun17 06:15
Novartis AG
0.70%
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
23Jun17 17:00
Novartis AG
0.70%
NEJM publishes full analysis of Rydapt® (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
23Jun17 09:40
Novartis AG
0.70%
Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
23Jun17 07:40
Novartis AG
0.70%
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
23Jun17 07:35
Novartis AG
0.70%
Novartis pivotal CTL019 6-month follow-up data show durable remission rates in children, young adults with r/r B-cell ALL
22Jun17 22:42
Novartis AG
0.70%
Novartis combination targeted therapy Tafinlar® + Mekinist® receives FDA approval for BRAF V600E mutant metastatic non-small cell lung cancer (NSCLC)
22Jun17 06:15
Novartis AG
0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
22Jun17 06:15
Novartis AG
0.70%
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
21Jun17 06:15
Novartis AG
0.70%
Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance
20Jun17 06:15
Novartis AG
0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:15
Novartis AG
0.70%
Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval
20Jun17 06:10
Novartis AG
0.70%
Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden
19Jun17 06:15
Novartis AG
0.70%
Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases
17Jun17 06:15
Novartis AG
0.70%
Novartis International AG: New patient survey highlights need for more action to help severe asthma patients gain control of their disease
15Jun17 19:00
Novartis AG
0.70%
FDA accepts Sandoz regulatory submission for a generic version of Advair Diskus®
15Jun17 06:15
Novartis AG
0.70%
Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years
08Jun17 21:30
Novartis AG
0.70%
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
07Jun17 16:30
Novartis AG
0.70%
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
06Jun17 06:15
Novartis AG
0.70%
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
05Jun17 21:05
Novartis AG
0.70%
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05Jun17 12:15
Novartis AG
0.70%
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
04Jun17 14:00
Novartis AG
0.70%
Novartis landmark study of Tafinlar® + Mekinist® demonstrates durable survival benefit at five years in patients with BRAF mutation-positive metastatic melanoma
02Jun17 06:15
Novartis AG
0.70%
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
31May17 06:10
Novartis AG
0.70%
Sandoz proposed biosimilars adalimumab and infliximab accepted for regulatory review by the European Medicines Agency
31May17 06:00
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
31May17 06:00
Novartis AG
0.70%
At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018
30May17 22:00
Novartis AG
0.70%
Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
«
1
2
3
4
5
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Actio Advisors
Align Research
Atrium Research
BlytheRay
BNP Paribas Exane - Sponsored Research
Brand Communications
BRR Media
Calvine Partners
Capital Access Group
Capital Markets Brokers
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
focusIR
Fundamental Research Corp
Galliano’s Latin Notes
goetzpartners securities Limited
H2 Radnor
Hardman & Co
Holland Advisors
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
NuWays
Paul Scott
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Resolve Research
SEAL Advisors Ltd
ShareSoc
Shore Capital
Small Cap Consumer Research LLC
StockBox
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
Turner Pope Investments
UK Investor Group
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cavendish
Couloir Capital
Dowgate Capital
First Berlin
First Sentinel
GSBR Research
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Clean Energy
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
Tennyson Securities
The Life Sciences Division
Turner Pope Investments
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
BNP Paribas Exane
BRR Media
Calvine Partners
Canaccord Genuity
Capital Access Group
Cavendish
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Degroof Petercam
DirectorsTalk
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
First Berlin
First Sentinel
Five Minute Pitch TV
Fundamental Research Corp
Galliano’s Latin Notes
Goodbody
H2 Radnor
Hannam & Partners
Hardman & Co
Holland Advisors
Hybridan
Inbound Capital
Independent Investment Research
InterAxS Global
Investec Bank
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Clean Energy
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
NuWays
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Quantum Research Group
QuotedData
RaaS - Research as a Service
Research Tree
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
Small Cap Consumer Research LLC
SP Angel
Stanford Capital Partners
Stifel
StockBox
Tamesis Partners
Tennyson Securities
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Contact
Sign Up
Sign In
Share: